Analysis of left ventricular mass in untreated men and in men treated with agalsidase-β: data from the Fabry Registry.
about
Enzyme replacement therapy for Anderson-Fabry diseaseTime to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry.The prevalence and epidemiology of genetic renal disease amongst adults with chronic kidney disease in Australia.Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.Fabry disease: multidisciplinary evaluation after 10 years of treatment with agalsidase Beta.Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease.Cardiac Troponin I: A Valuable Biomarker Indicating the Cardiac Involvement in Fabry Disease.Normal left-atrial structure and function despite concentric left-ventricular remodelling in a cohort of patients with Anderson-Fabry disease.Enzyme replacement therapy for Anderson-Fabry disease: A complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies.Pain in Fabry Disease: Practical Recommendations for Diagnosis and Treatment.The value of ECG parameters as markers of treatment response in Fabry cardiomyopathy.Echocardiographic and clinical findings in patients with Fabry disease during long-term enzyme replacement therapy: a nationwide Danish cohort study.Loss of base-to-apex circumferential strain gradient: A specific pattern of Fabry cardiomyopathy?Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: A multicenter Fabry Registry study.
P2860
Q26471010-11D914C8-3F88-469E-8269-86F0D126006EQ31060724-B19D0F99-6991-41C6-B872-A44A21D86EB1Q33858105-52DCC174-5410-4AC1-B0A3-7AE5C6017656Q33886219-B23A3CD1-3575-47F7-B78F-65C931D428E5Q34457667-6E779037-2EC9-4E23-A53C-B3749F0E1233Q35550696-36197CE6-D6C3-4A00-8037-50BD5C660AB2Q36056601-B0B573D5-D1F4-4A93-B0CC-594E82782372Q36061578-71C8CA5A-4F22-4E80-9FEE-41D82AB21C2BQ36309032-26A7EA11-9925-4698-998E-BF3C5672027AQ37352268-DCE8257E-3B5D-4011-9402-194E55CB7D3BQ43628771-A7692A9F-A826-4B6B-9EEA-54916932A686Q48091189-610D0C8D-35C2-4A78-8D83-F548E979A723Q48168782-C9A724E9-9B2F-47F9-98D1-B2C551C8D5E8Q54236852-F18B0E59-BEBB-43FD-AF15-7B031A92C505
P2860
Analysis of left ventricular mass in untreated men and in men treated with agalsidase-β: data from the Fabry Registry.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Analysis of left ventricular m ...... data from the Fabry Registry.
@ast
Analysis of left ventricular m ...... data from the Fabry Registry.
@en
type
label
Analysis of left ventricular m ...... data from the Fabry Registry.
@ast
Analysis of left ventricular m ...... data from the Fabry Registry.
@en
prefLabel
Analysis of left ventricular m ...... data from the Fabry Registry.
@ast
Analysis of left ventricular m ...... data from the Fabry Registry.
@en
P2093
P2860
P356
P1433
P1476
Analysis of left ventricular m ...... data from the Fabry Registry.
@en
P2093
Ademola Abiose
Ales Linhart
C Ronald Scott
Dana Beitner-Johnson
David G Warnock
Dominique P Germain
Fabry Registry
Frank Weidemann
Gustavo Cabrera
Ilkka Kantola
P2860
P2888
P304
P356
10.1038/GIM.2013.53
P407
P577
2013-05-23T00:00:00Z